Product image of Minirin Melt (Desmopressin) supplied by GNH India

Minirin Melt

Active Ingredient:
Desmopressin
Origin:
EU

Minirin Melt (Desmopressin)

Desmopressin, the active ingredient in Minirin Melt, is a vasopressin analog presented as an oral melt for oral use. It is employed to treat central diabetes insipidus and nocturnal enuresis by reducing excessive urine production.

GNH India supplies Minirin Melt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for regulated medicines across multiple regions. Its network includes distribution hubs in Europe, Asia and Africa.

Manufacturer / TM Owner

Ferring Léciva A.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Desmopressin acts on the antidiuretic hormone pathway to correct water balance disorders, making it useful in specific clinical settings.

  • Central diabetes insipidus: reduces polyuria and thirst by increasing water reabsorption in the kidneys.
  • Nocturnal enuresis (bedwetting): lowers nighttime urine output, helping children and adults achieve dry nights.
  • Primary nocturnal enuresis in children: improves bladder control during sleep by concentrating urine.

How It Works

  • Desmopressin is a synthetic analogue of vasopressin that selectively binds to V2 receptors on the basolateral membrane of renal collecting‑duct cells. Activation of V2 receptors stimulates adenylate cyclase, raising intracellular cyclic AMP, which promotes insertion of aquaporin‑2 water channels into the apical membrane. The increased water permeability enhances free water reabsorption, concentrating urine and reducing urine volume.

Side Effects

Desmopressin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Nausea: occasional upset stomach.
  • Abdominal discomfort: mild cramps or pain.
  • Mild hyponatremia: slight reduction in serum sodium without symptoms.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Severe hyponatremia: marked sodium loss that can lead to confusion or seizures.
  • Water intoxication: excessive fluid retention causing edema and pulmonary congestion.
  • Seizures: neurological events linked to profound hyponatremia.
  • Allergic reactions: rash, itching or swelling of the face.
  • Blood pressure changes: hypotension or hypertension in susceptible individuals.

Precautions & Warnings

When prescribing Desmopressin, clinicians should observe several precautionary measures to minimise risk.

  • Monitor serum sodium: check electrolytes before and during therapy to detect hyponatremia.
  • Adjust dose in renal impairment: reduced clearance may increase drug exposure.
  • Limit fluid intake: advise patients to avoid excessive drinking while on treatment.
  • Use caution in the elderly: age‑related renal changes raise the risk of water retention.
  • Contraindicated in existing hyponatremia: do not initiate therapy if sodium levels are already low.
  • Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Avoid Interactions

Desmopressin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Vasopressin antagonists (e.g., conivaptan): block V2 receptors and negate Desmopressin’s effect.
  • Loop or thiazide diuretics: increase risk of hyponatremia by enhancing water retention.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may potentiate antidiuretic action and raise sodium loss.

Moderate Interactions (Monitor Closely)

  • Selective serotonin reuptake inhibitors (SSRIs): combined use can predispose to hyponatremia.
  • Antihypertensive agents: additive blood‑pressure lowering effect may occur.
  • Alcohol: may increase fluid intake and exacerbate water‑retention risk.

Frequently Asked Questions

Minirin Melt contains desmopressin and is prescribed for central diabetes insipidus, a disorder that causes excessive urine output, and for nocturnal enuresis, which is nighttime bedwetting in children or adults.

Desmopressin is a synthetic analogue of the hormone vasopressin. It selectively activates V2 receptors in the kidney’s collecting ducts, raising cyclic AMP levels and promoting insertion of aquaporin‑2 channels, which increase water reabsorption and concentrate the urine.

The dose of Minirin Melt is individualized. A qualified prescriber determines the appropriate strength, frequency and duration based on the patient’s condition, age, renal function and response to therapy.

Safety data for desmopressin in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and clinicians should weigh potential benefits against risks before prescribing to pregnant or nursing women.

To order Minirin Melt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Desmopressin is a selective V2‑receptor agonist, offering a more targeted antidiuretic effect than non‑selective vasopressin analogues. It generally has a lower risk of vasoconstrictive side effects and is preferred for central diabetes insipidus and nocturnal enuresis when a precise water‑retention action is needed.

Store Minirin Melt at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and avoid exposure to direct sunlight to maintain stability.

Minirin Melt is taken orally. The tablet is placed on the tongue and allowed to dissolve, or it can be swallowed with a small amount of water, following the prescriber’s instructions regarding timing relative to meals.

The most serious risks include severe hyponatremia, which can lead to confusion, seizures or coma, and water intoxication resulting in pulmonary or cerebral edema. Patients should be monitored for signs of electrolyte imbalance, especially during the initial weeks of therapy.

Minirin Melt should not be used in patients with existing hyponatremia, uncontrolled hypertension, or those taking vasopressin antagonists. Caution is also advised for individuals with severe renal impairment or a history of water‑retention disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.